Corcept Therapeutics Quarterly Cash Flow Statement
NASDAQ: CORTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Corcept Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Corcept Therapeutics generated $33.5 million of operating cash flow and spent $2.5 million on capital expenditures. That left free cash flow of $31.0 million, a free-cash-flow margin of 12.1% of revenue. Free cash flow was down 29.9% from the prior year's $44.2 million.
Summary generated from market data by MetaCap's automated system. Methodology
Corcept Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 42.99M | -31.76M | 24.29M | 19.67M | 35.15M | 20.55M | 30.75M | 47.21M | 35.49M | 27.76M | 31.36M | 31.38M |
| Net Income growth (YoY) | +22.30% | -254.58% | -21.00% | -58.34% | -0.96% | -25.99% | -1.94% | +50.47% | +28.92% | +74.83% | +88.87% | -9.33% |
| Depreciation & Amortization | 863.00K | 598.00K | 289.00K | -71.00K | 469.00K | 462.00K | 281.00K | 318.00K | 76.00K | 120.00K | 214.00K | 232.00K |
| Stock-Based Compensation | 29.42M | 23.04M | 20.77M | 22.88M | 19.02M | 21.83M | 16.80M | 16.10M | 15.21M | 13.25M | 13.06M | 12.88M |
| Change in Working Capital | -63.75M | 14.53M | 19.22M | 2.17M | -13.49M | 5.33M | 2.92M | -5.48M | 12.04M | -24.12M | -7.01M | 5.97M |
| Operating Cash Flow | 33.54M | -16.77M | 38.45M | 54.48M | 44.30M | 4.77M | 60.06M | 73.29M | 41.19M | 23.76M | 5.53M | 52.91M |
| Capital Expenditures | -2.53M | -201.00K | -50.00K | 0 | -57.00K | -104.00K | -121.00K | -1.64M | -416.00K | 0 | 0 | -37.00K |
| Investing Cash Flow | -29.24M | 4.54M | -11.84M | 14.64M | 70.13M | -3.17M | -64.36M | -44.04M | -60.19M | -9.01M | 17.10M | -109.57M |
| Share Repurchases | 0 | 0 | 0 | -42.46M | -103.02M | -27.43M | 0 | -11.71M | -3.48M | -476.00K | 0 | 0 |
| Financing Cash Flow | -2.04M | 760.00K | -31.22M | -46.41M | -102.93M | -39.80M | -4.56M | -21.09M | -2.15M | -543.00K | 766.00K | -3.92M |
| Net Change in Cash | 2.30M | -11.76M | -4.64M | 22.39M | 12.93M | -37.85M | -9.62M | 8.70M | -21.16M | 14.20M | 23.75M | -60.58M |
| Free Cash Flow | 31.02M | -16.97M | 38.40M | 54.48M | 44.24M | 4.67M | 59.94M | 71.66M | 40.77M | 23.76M | 5.53M | 52.87M |
This table shows 12 quarterly periods of Corcept Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CORT's reporting calendar. What is a cash flow statement?